DNLI SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Nov 3, 2026

8-K

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 6, 2026

8-K

Denali Therapeutics Completes Sale of Rare Pediatric Disease Priority Review Voucher

Jul 27, 2026

8-K

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Jun 18, 2026

8-K

Denali Therapeutics Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 3, 2026

8-K

Biogen and Denali Discontinue Development of BIIB122 in Idiopathic Parkinson’s Disease Following Phase 2b LUMA Study Results

May 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

FIXED PRICE OFFERING - COMMON STOCK | Offering amount: $199,977,135 | Shares: 11,428,571 | Price: $17.500 | Bank: Goldman Sachs & Co. LLC

Dec 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Goldman Sachs & Co. LLC

Dec 9, 2025

424B5

SHELF OFFERING | Shares amount: 10,377,359 | Share price: $26.50 | Offering amount: $275,000,014.00 | Bank: Goldman Sachs & Co. LLC, J.P. Morgan, Jefferies, Berenberg, Cantor, H.C. Wainwright & Co.

Oct 20, 2022

424B5

PENDING OFFERING | Bank: Goldman Sachs & Co. LLC, J.P. Morgan, Jefferies, Berenberg, Cantor, H.C. Wainwright & Co.

Oct 18, 2022

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 29, 2020

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 27, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Feb 27, 2025

S-3ASR

SHARE RESALE REGISTRATION | Shares amount: 29,290,754 | Share price: $21.00 | Warrants amount: 26,046,0651

Mar 22, 2024

Form D - Notice of Exempt Offering of Securities - Item 06b

Mar 1, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 21, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 18, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 18, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Chin Peter Scott (Reporting)

Sep 9, 2026

144

Form 144 - Report of proposed sale of securities

Sep 4, 2026

Thornberry Nancy (Reporting)

Sep 4, 2026

Schuth Alexander O. (Reporting)

Sep 3, 2026

144

Form 144 - Report of proposed sale of securities

Sep 2, 2026

144

Form 144 - Report of proposed sale of securities

Sep 1, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Oct 7, 2019

LETTER

Form UPLOAD - SEC-generated letter

Oct 7, 2019

CORRESP

Form CORRESP - Correspondence

Sep 11, 2019

LETTER

Form UPLOAD - SEC-generated letter

Aug 16, 2019

LETTER

Form UPLOAD - SEC-generated letter

Aug 16, 2019

CORRESP

Form CORRESP - Correspondence

Jul 16, 2019

Denali Therapeutics Inc. DNLI · SEC Filings